First Complementary Foods and the Infant Gastrointestinal Microbiota
Conditions:   Healthy Participants;   Infants;   Gastrointestinal Microbiota Interventions:   Other: Infant fruit;   Other: Infant vegetable;   Other: Infant meat;   Other: Infant grain Sponsors:   University of Delaware;   American Society for Nutrition Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2022 Category: Research Source Type: clinical trials

Randomised Three-way Cross Over Study to Determine Optimal Absorption of Single Dose Omega-3
Condition:   Optimal Gastrointestinal Absorption of Omega-3 Interventions:   Drug: Product 1 - AquaCelle Fish Oil Triglyceride;   Drug: Product 2 - AquaCelle Fish Oil Ethyl Ester;   Drug: Product 3 - Standard Fish Oil Triglyceride Sponsor:   RDC Clinical Pty Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2022 Category: Research Source Type: clinical trials

First Complementary Foods and the Infant Gastrointestinal Microbiota
Conditions:   Healthy Participants;   Infants;   Gastrointestinal Microbiota Interventions:   Other: Infant fruit;   Other: Infant vegetable;   Other: Infant meat;   Other: Infant grain Sponsors:   University of Delaware;   American Society for Nutrition Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2022 Category: Research Source Type: clinical trials

Randomised Three-way Cross Over Study to Determine Optimal Absorption of Single Dose Omega-3
Condition:   Optimal Gastrointestinal Absorption of Omega-3 Interventions:   Drug: Product 1 - AquaCelle Fish Oil Triglyceride;   Drug: Product 2 - AquaCelle Fish Oil Ethyl Ester;   Drug: Product 3 - Standard Fish Oil Triglyceride Sponsor:   RDC Clinical Pty Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2022 Category: Research Source Type: clinical trials

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours
Conditions:   Endometrial Cancer;   Gastric Cancer;   Metastatic Castration-resistant Prostate Cancer;   Ovarian Cancer;   Colorectal Cancer Interventions:   Drug: Datopotamab deruxtecan (Dato-DXd);   Drug: AZD5305;   Drug: Durvalumab;   Drug: Capecitabine;   Drug: 5-Fluorouracil;   Drug: Nivolumab;   Drug: Carboplatin;   Drug: Leucovorin LV;   Drug: Bevacizumab Sponsors:   AstraZeneca;   Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Conditions:   Gastrointestinal Stromal Tumor (GIST);   Digestive System Disease;   Gastrointestinal Diseases;   Metastatic Cancer Intervention:   Drug: IDRX-42 Sponsor:   IDRx, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours
Conditions:   Endometrial Cancer;   Gastric Cancer;   Metastatic Castration-resistant Prostate Cancer;   Ovarian Cancer;   Colorectal Cancer Interventions:   Drug: Datopotamab deruxtecan (Dato-DXd);   Drug: AZD5305;   Drug: Durvalumab;   Drug: Capecitabine;   Drug: 5-Fluorouracil;   Drug: Nivolumab;   Drug: Carboplatin;   Drug: Leucovorin LV;   Drug: Bevacizumab Sponsors:   AstraZeneca;   Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Conditions:   Gastrointestinal Stromal Tumor (GIST);   Digestive System Disease;   Gastrointestinal Diseases;   Metastatic Cancer Intervention:   Drug: IDRX-42 Sponsor:   IDRx, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours
Conditions:   Endometrial Cancer;   Gastric Cancer;   Metastatic Castration-resistant Prostate Cancer;   Ovarian Cancer;   Colorectal Cancer Interventions:   Drug: Datopotamab deruxtecan (Dato-DXd);   Drug: AZD5305;   Drug: Durvalumab;   Drug: Capecitabine;   Drug: 5-Fluorouracil;   Drug: Nivolumab;   Drug: Carboplatin;   Drug: Leucovorin LV;   Drug: Bevacizumab Sponsors:   AstraZeneca;   Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Conditions:   Gastrointestinal Stromal Tumor (GIST);   Digestive System Disease;   Gastrointestinal Diseases;   Metastatic Cancer Intervention:   Drug: IDRX-42 Sponsor:   IDRx, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours
Conditions:   Endometrial Cancer;   Gastric Cancer;   Metastatic Castration-resistant Prostate Cancer;   Ovarian Cancer;   Colorectal Cancer Interventions:   Drug: Datopotamab deruxtecan (Dato-DXd);   Drug: AZD5305;   Drug: Durvalumab;   Drug: Capecitabine;   Drug: 5-Fluorouracil;   Drug: Nivolumab;   Drug: Carboplatin;   Drug: Leucovorin LV;   Drug: Bevacizumab Sponsors:   AstraZeneca;   Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Conditions:   Gastrointestinal Stromal Tumor (GIST);   Digestive System Disease;   Gastrointestinal Diseases;   Metastatic Cancer Intervention:   Drug: IDRX-42 Sponsor:   IDRx, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours
Conditions:   Endometrial Cancer;   Gastric Cancer;   Metastatic Castration-resistant Prostate Cancer;   Ovarian Cancer;   Colorectal Cancer Interventions:   Drug: Datopotamab deruxtecan (Dato-DXd);   Drug: AZD5305;   Drug: Durvalumab;   Drug: Capecitabine;   Drug: 5-Fluorouracil;   Drug: Nivolumab;   Drug: Carboplatin;   Drug: Leucovorin LV;   Drug: Bevacizumab Sponsors:   AstraZeneca;   Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Conditions:   Gastrointestinal Stromal Tumor (GIST);   Digestive System Disease;   Gastrointestinal Diseases;   Metastatic Cancer Intervention:   Drug: IDRX-42 Sponsor:   IDRx, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
Condition:   Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months Intervention:   Drug: Esomezol Cap Sponsor:   Hanmi Pharmaceutical Company Limited Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 4, 2022 Category: Research Source Type: clinical trials